Prediabetes in metabolic syndrome
https://doi.org/10.15829/1560-4071-2025-6538
Abstract
The article analyzes modern concepts of the pathogenesis, diagnosis and impact on the prognosis of prediabetes in metabolic syndrome. An overview of modern potential of non-drug and drug therapy for carbohydrate metabolism disorders in metabolic syndrome is provided, and management of other metabolic syndrome components in patients with prediabetes are analyzed.
About the Author
A. Yu. Babenko
Almazov National Research Medical Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
None
References
1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48 (1 Suppl 1):S27-S49. doi:10.2337/dc25-S002.
2. Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-12. (In Russ.) doi:10.14341/DM2004116-17.
3. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z.
4. Højlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan Med J. 2014;61(7):B4890.
5. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-36. doi:10.1161/ATVBAHA.107.151092.
6. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316. doi:10.1210/er.2015-1137.
7. Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012;122(1):153-62. doi:10.1172/JCI59660.
8. Gou Y, Glat M, Damian V, et al. AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes. J Clin Invest. 2025;135(10):e189842. doi:10.1172/JCI189842.
9. Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol Metab Syndr. 2019;11:74. doi:10.1186/s13098-019-0468-0.
10. Møller CL, Vistisen D, Færch K, et al. Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. J Clin Endocrinol Metab. 2016;101(2):485-93. doi:10.1210/jc.2015-3133.
11. Hartstra AV, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38(1):159-65. doi:10.2337/dc14-0769.
12. Drapkina OM, Korneeva ON. Gut microbiota and obesity: Pathogenetic relationships and ways to normalize the intestinal microflora. Therapeutic Archive. 2016;88(9):135-42. (In Russ.) doi:10.17116/terarkh2016889135-142.
13. Kononova YA, Likhonosov NP, Babenko AY. Metformin: Expanding the Scope of Application — Starting Earlier Than Yesterday, Canceling Later. Int. J. Mol.Sci. 2022;23:2363. doi:10.3390/ijms23042363.
14. Babenko AY. Metformin in prediabetes: key mechanisms for the prevention of diabetes and cardiometabolic risks. Meditsinskiy sovet = Medical Council. 2022;(10):96-103. (In Russ.) doi:10.21518/2079-701X-2022-16-10-96-103.
15. Holm JC, Gamborg M, Ward LC, et al. Tracking of leptin, soluble leptin receptor, and the free leptin index during weight loss and regain in children. Obes Facts. 2011;4(6): 461-8. doi:10.1159/000335121.
16. Bourebaba L, Marycz K. Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. J Clin Med. 2019;8(12):2033. doi:10.3390/jcm8122033.
17. Jayakrishnan B. Hepato-pancreatic fat-fetuin A based axis in context of diabetes and its reversal. Int J Adv Med. 2023;10:117-9. doi:10.18203/2349-3933.ijam20223413.
18. Lee CH, Lui DTW, Lam KSL. Adipocyte Fatty Acid-Binding Protein, Cardiovascular Diseases and Mortality. Front Immunol. 2021;12:589206. doi:10.3389/fimmu.2021.589206.
19. Heiker JT. Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. J Pept Sci. 2014;20(5):299-306. doi:10.1002/psc.2621.
20. Aibara D, Matsuo K, Yamano S, Matsusue K. Insulin induces expression of the hepatic vaspin gene. Endocr J. 2020;67(1):9-14. doi:10.1507/endocrj.EJ19-0276.
21. Stefan N, Fritsche A, Schick F, Häring HU. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol. 2016;4(9):789-98. doi:10.1016/S2213-8587(16)00082-6.
22. Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27(1):49-57. doi:10.1038/s41591-020-1116-9.
23. Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665-73. doi:10.2337/dc09-1939.
24. Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297.
25. Hsu JC, Yang YY, Chuang SL, et al. Prediabetes increases the risk of major limb and cardiovascular events. Cardiovasc Diabetol. 2023;22(1):348. doi:10.1186/s12933-023-02085-y.
26. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-62. doi:10.1016/S2213-8587(24)00316-4.
27. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines, on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.
28. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16. doi:10.1056/NEJMoa2206038.
29. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008;102(12A):5L-9L. doi:10.1016/j.amjcard.2008.09.067.
30. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156(1):112-9. doi:10.1016/j.ahj.2008.03.005.
31. Hoogwerf BJ. Statins may increase diabetes, but benefit still outweighs risk. Cleve Clin J Med. 2023;90(1):53-62. doi:10.3949/ccjm.90a.22069.
32. Banach M, Surma S, Reiner Z, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol. 2022;21(1):263. doi:10.1186/s12933-022-01684-5.
33. Maki KC, Ridker PM, Brown WV, et al. The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17-29. doi:10.1016/j.jacl.2014.02.012.
Review
For citations:
Babenko A.Yu. Prediabetes in metabolic syndrome. Russian Journal of Cardiology. 2025;30(1S):6538. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6538
Views:
199
Email this article 